Crinetics Pharmaceuticals, Inc. (CRNX)

Market Cap	4.79B
Revenue (ttm)	1.54M
Net Income (ttm)	-423.10M
Shares Out	94.89M
EPS (ttm)	-4.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,113,597
Open	49.00
Previous Close	49.31
Day's Range	48.58 - 50.98
52-Week Range	24.10 - 60.25
Beta	0.20
Analysts	Buy
Price Target	71.00 (+40.62%)
Earnings Date	Nov 6, 2025

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2018
• Employees: 437
• Stock Exchange: NASDAQ
• Ticker Symbol: CRNX
• Website: https://www.crinetics.com

Financial Performance

In 2024, Crinetics Pharmaceuticals's revenue was $1.04 million, a decrease of -74.11% compared to the previous year's $4.01 million. Losses were -$298.41 million, 39.1% more than in 2023.

Analyst Summary

According to 11 analysts, the average rating for CRNX stock is "Buy." The 12-month stock price target is $71.0, which is an increase of 40.62% from the latest price.

Price Target

$71.0

(40.62% upside)

Analyst Consensus: Buy